AstraZeneca PLC (LON:AZN – Get Free Report) has been assigned an average rating of “Moderate Buy” from the nine analysts that ...

AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Berenberg Bank in a report issued on Monday, MarketBeat reports. They presently have a GBX 140 ...

AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates ...

Analysis of AstraZeneca's market potential, including China and IRA impacts, and the importance of key readouts in 2025 for ...

In 2023, the global breast cancer drug market is projected to be worth USD 10,733.1 million.  Between 2023 and 2033, the demand for breast cancer drugs is expected to expand at a CAGR of 1.1%, ...

The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II drugs for Malignant Mesothelioma have a 42% phase ...

INR:2526. what is handicap in betting football Pharmaceutical giants' Q3 performance comparison: AZ and Merck have the ...

AstraZeneca's Lynparza for pancreatic cancer receives support from FDA advisory committee Hainan Province announces the official im ...

INR:0260. rummy partner app AstraZeneca/Merck Lynparza (Lynparza) received 3 approvals in Japan New mechanism! Inflammatory bowel disease is expected to usher i ...

INR:1736. rivalry bet apk AstraZeneca/Merck Lynparza (Lynparza) received 3 approvals in Japan Propharma: Memantine Hydrochloride Tablets Obtained Drug Registratio ...